Inspire Advisors LLC Purchases Shares of 5,378 TransMedics Group, Inc. $TMDX

Inspire Advisors LLC acquired a new position in TransMedics Group, Inc. (NASDAQ:TMDX) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 5,378 shares of the company’s stock, valued at approximately $603,000.

Other hedge funds have also recently made changes to their positions in the company. Yorktown Management & Research Co Inc purchased a new stake in TransMedics Group in the third quarter valued at approximately $393,000. Amalgamated Bank boosted its position in shares of TransMedics Group by 2.5% during the third quarter. Amalgamated Bank now owns 9,827 shares of the company’s stock worth $1,103,000 after buying an additional 241 shares during the period. Evergreen Capital Management LLC grew its stake in shares of TransMedics Group by 18.4% in the third quarter. Evergreen Capital Management LLC now owns 2,676 shares of the company’s stock valued at $300,000 after buying an additional 415 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new stake in shares of TransMedics Group in the 3rd quarter valued at $1,597,000. Finally, Nordea Investment Management AB acquired a new position in TransMedics Group during the 3rd quarter worth about $4,070,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Down 1.0%

Shares of TransMedics Group stock opened at $141.93 on Wednesday. The company has a quick ratio of 7.13, a current ratio of 7.69 and a debt-to-equity ratio of 1.43. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $156.00. The company has a market capitalization of $4.85 billion, a P/E ratio of 57.46 and a beta of 2.03. The company has a 50 day moving average of $131.69 and a 200 day moving average of $122.75.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.29. The company had revenue of $143.82 million for the quarter, compared to the consensus estimate of $145.33 million. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The company’s quarterly revenue was up 32.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.12 EPS. As a group, research analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of TransMedics Group in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of TransMedics Group from a “hold” rating to a “buy” rating in a report on Sunday, December 28th. Canaccord Genuity Group upped their target price on shares of TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Morgan Stanley raised their price target on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 2nd. Finally, Needham & Company LLC upped their price objective on TransMedics Group from $148.00 to $166.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, TransMedics Group has an average rating of “Moderate Buy” and a consensus target price of $144.25.

Insiders Place Their Bets

In related news, insider Anil P. Ranganath sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total transaction of $435,660.00. Following the completion of the sale, the insider owned 13,955 shares in the company, valued at $2,026,545.10. The trade was a 17.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David Weill sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total value of $693,200.00. Following the completion of the transaction, the director directly owned 12,134 shares of the company’s stock, valued at $1,682,257.76. This trade represents a 29.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 13,062 shares of company stock valued at $1,797,634 over the last quarter. Corporate insiders own 7.00% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.